Clinical Trials For frontotemporal dementia To Start By 2013


Clinical Trials For frontotemporal dementia To Start By 2013

A neurodegenerative disease, frontotemporal dementia starts with silence and damages personality traits and then affects the brain. It gets very late for doctors to address the problem and till the time they get to know about, a person suffering from it, is left with very less time.

The disease was first discovered some 100 years back, but then also researchers have not been able to find probable reasons as well as treatment of the problem. It has also been found those maximum survival years of person after diagnosis of disease is not more than eight years.

However, researchers at the University of California have identified drugs that can treat the rare neurodegenerative problem. It is said that the study researchers are going to initiate clinical trials for the same by 2013.

Dr. Bruce L. Miller, who is a Professor of neurology and psychiatry in University of California, said that it is high time that researchers should know that there are different subtypes of dementia. "I think at least some subtypes of frontotemporal dementia will be the first neurodegenerative diseases we find a cure for", said Miller.

Miller further said that there are chances that the development helps understanding Alzheimer's disease in a better way.

Latest News

Deutsche Bank Q3 Loss may be a Record One in a Decade
Volkswagen Scandal Worries the City of Wolfsburg
Strong Component Sale and Weak Won help Samsung’s Third Quarter Profits
Is the U.S. Shale Oil Boom Heading Towards the Beginning of Its End?
Volkswagen Plans to Launch a Recall in January and Fix the Affected Diesel Cars
BOJ Keep Record Stimulus Unchanged
BP Plc will Pay $20 Billion as Penalties for the Deadly Oil Spill of 2010
Ben Bernanke says Larger Number of Executives Involved in 2008 Financial Crisis
United’s New CEO Oscar Muñoz Aims at Improving relation with Workers
The September Job Number Hint at a Sluggish Patch
First Data Launches its IPO, Targets to Raise Up to $3.7 Billion
ConAgra’s Head Quarter Move Announcement gets Positive but ‘Muted’